Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REVISION
2021-000183-29Phase 3Active
- Sponsor
- University Hospital Tübingen
- Start
- Jul 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in central retinal artery occlusion (CRAO) comparing Intravenous alteplase with Placebo (2 arms). Primary endpoint: Functional visual recovery at Visit 3. Started Jul 2021; status: active.
02
Drugs
tissue-plasminogen activator
03
Conditions
central retinal artery occlusion (CRAO)
Beyond the preview
Go deeper on 2021-000183-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000183-29.